Drug intelligence / Profile preview

curcumagalactomannoside

Development stage
Preclinical
Lead developer
Akay Bioactives
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

**Curcumagalactomannoside** is a proprietary, food-grade curcumin formulation marketed as **CurQfen**. It is a water-dispersible, non-covalent complex of turmeric-derived curcuminoids with a fenugreek galactomannan dietary-fiber matrix, designed to increase systemic exposure to unconjugated free curcuminoids relative to conventional curcumin preparations. It was originated by Akay and is sold as a nutraceutical ingredient for oral dietary-supplement products. Human studies have evaluated it for knee osteoarthritis, occupational stress-related symptoms, safety, bioavailability, and other wellness-related outcomes; a six-week active-controlled knee-osteoarthritis study reported improvements in pain and function. In vitro, CGM induced ROS-associated mitochondrial apoptosis in HeLa cervical-cancer cells, but it is not an approved oncology therapy. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27043120/))

Brand names
CurQfen
Other names
CGMcurcumin-galactomannoside complexcurcumagalactomannosides
02

Targets

HDAC (HDAC family)CREBBP (CREB-binding protein)LY96 (Myeloid differentiation factor 2)

Beyond the preview

Go deeper on curcumagalactomannoside.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on curcumagalactomannoside.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call